Lightlake Therapeutics (LLTPD) 3.5800 $LLTPD
Binge Eating Disorder Pipeline Review, H2 2015
M2 - Tue Feb 02, 11:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/2px4r5/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Binge Eating Disorder Overview - Therapeutics Development - Pipeline Products for Binge Eating Disorder - Overview - Pipeline Products for Binge Eating Disorder - Comparative Analysis - Binge Eating Disorder - Therapeutics under Development by Companies - Binge Eating Disorder - Therapeutics under Investigation by Universities/Institutes - Binge Eating Disorder - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Binge Eating Disorder - Products under Development by Companies - Binge Eating Disorder - Products under Investigation by Universities/Institutes - Binge Eating Disorder - Companies Involved in Therapeutics Development - Eli Lilly and Company - Heptares Therapeutics Limited - Lightlake Therapeutics Inc. - Omeros Corporation - Polleo Pharma Limited - Sunovion Pharmaceuticals Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/2p...nge_eating
TEVA: 54.58 (-0.40), LLY: 80.66 (+0.07), OMER: 11.39 (+0.23)
Lightlake Therapeutics Inc.Announces Adapt Pharma Limited to Offer All U.S. High Schools a Free Narcan(R) (Naloxone Hydrochloride) Nasal Spray and Fund School-Based Opioid Overdose Education
GlobeNewswire - Wed Jan 27, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's commercial partner for NARCAN(R) Nasal Spray, has announced two national programs at the Clinton Health Matters Initiative Activation Summit to assist in efforts to address the growing risk of opioid overdose among American high school students.
Traders Look to Upside - Complementary Research on Kingfisher, Lafargeholcim, Yahoo Japan and Lightlake Therapeutics
ACCESSWIRE - Wed Jan 20, 8:20AM CST
NEW YORK, NY / ACCESSWIRE / January 20, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Kingfisher PLC (OTC: KGFHY), Lafargeholcim Ltd. (OTC: HCMLY), Yahoo Japan Corp. (OTC: YAHOY) and Lightlake Therapeutics Inc. (OTC: LLTP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Facilitates NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Access to 62,000 State and Local Public Entities
GlobeNewswire - Tue Jan 19, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders announced today that Adapt Pharma Limited ("Adapt" , Lightlake's commercial partner for NARCAN(R) Nasal Spray, has, in support of White House efforts to address the opioid overdose epidemic and a community forum in Knoxville, Tennessee, announced that it has reached an agreement to facilitate the purchase of NARCAN(R) Nasal Spray by offering its discounted public interest price to 62,000 agencies in state and local government and the non-profit sector.
Lightlake Therapeutics Inc. Announces Collaboration With NIDA and the Perelman School of Medicine at the University of Pennsylvania
GlobeNewswire - Wed Dec 23, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders, announced today that an opioid antagonist drug will be tested in patients with Cocaine Use Disorder at the University of Pennsylvania. The study will be conducted by the Department of Psychiatry at the Perelman School of Medicine at the University of Pennsylvania, and is beginning recruitment in December 2015.
Lightlake Therapeutics Inc. Receives Milestone Payment for U.S. Food and Drug Administration Approval of NARCAN(R) (Naloxone Hydrochloride) Nasal Spray
GlobeNewswire - Tue Dec 15, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders, announced today that it has received a $2 million milestone payment from Adapt Pharma Limited ("Adapt" . This milestone payment was triggered by the U.S. Food and Drug Administration ("FDA" approval of NARCAN(R) (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt, Lightlake's commercial partner. The FDA approved NARCAN(R) Nasal Spray on November 18, 2015. Lightlake also expects to receive a $2.5 million milestone payment from Adapt after the prospective first commercial sale of NARCAN(R) Nasal Spray in the United States.
Drug Addiction - Pipeline Review Report, H2 2015
M2 - Fri Dec 04, 6:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/j3rm9n/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H2 2015" report to their offering. Drug Addiction - Pipeline Review, H2 2015 Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Drug Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Drug Addiction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Drug Addiction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Drug Addiction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics Ltd - Aphios Corporation - Astellas Pharma Inc. - Curemark, LLC - Embera NeuroTherapeutics, Inc. - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lightlake Therapeutics Inc. - Omeros Corporation - Rottapharm SpA - Saniona AB - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/j3..._addiction
TEVA: 54.58 (-0.40), OMER: 11.39 (+0.23)
NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Approved by U.S. Food and Drug Administration
GlobeNewswire - Thu Nov 19, 7:30AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders announced today that the U.S. Food and Drug Administration (FDA) has approved NARCAN(R) (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt Pharma Limited ("Adapt" , Lightlake's partner.
Lightlake Therapeutics Inc. Announces FDA Accepts for Review Adapt Pharma Limited's NARCAN(R) (Naloxone Hydrochloride) Nasal Spray NDA and Grants Priority Review Status
GlobeNewswire - Fri Sep 25, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has had a New Drug Application (NDA) accepted for filing by the U.S. Food and Drug Administration (FDA) for NARCAN(R) (naloxone hydrochloride) Nasal Spray and Priority Review has been granted. NARCAN(R) Nasal Spray had previously been granted Fast Track Designation by the FDA and Adapt submitted an NDA in July 2015.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Submits NDA To FDA For Narcan® (naloxone) Nasal Spray
PR Newswire - Wed Jul 29, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a specialty pharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Narcan® (naloxone) Nasal Spray, an investigational drug intended to treat opioid overdose.
Drug Addiction Pipeline Review, H1 2015 - 11 Companies & 26 Drug Profiles
M2 - Thu Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zp3lh3/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Aphios Corporation - Curemark, LLC - Embera NeuroTherapeutics, Inc. - Gilead Sciences, Inc. - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lightlake Therapeutics Inc. - Omeros Corporation - Rottapharm SpA - Teva Pharmaceutical Industries Limited Drug Profiles - (oxazepam metyrapone) - ADX-71441 - ADX-88178 - cannabidiol - CM-1212 - CR-5542 Series - dronabinol - Drug for Dependence - GS-6637 - ibudilast - LT-22 - MC-100093 - Methoxycoronaridine - OMS-527 - Small Molecule for Drug Addiction - Small Molecule to Activate Kappa Opioid Receptor for CNS - Small Molecule to Inhibit BRD for Cocaine Dependence - Small Molecule to Inhibit Kappa Opioid Receptor for CNS - Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Small Molecules to Inhibit DAT and SERT for CNS Disorders - Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders - TV-1380 - Vaccine for Cocaine Addiction - Vaccine for Cocaine Addiction - Vaccine for Methamphetamine Addiction For more information visit http://www.researchandmarkets.com/research/zp..._addiction
GILD: 87.76 (+2.22), TEVA: 54.58 (-0.40), OMER: 11.39 (+0.23)
Binge Eating Disorder Pipeline Review 2015 - 5 Companies & 5 Drug Profiles
M2 - Wed Jun 24, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/46nvx8/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Heptares Therapeutics Ltd. - Lightlake Therapeutics Inc. - Omeros Corporation - Polleo Pharma Limited - Teva Pharmaceutical Industries Limited Drug Profiles - armodafinil - naloxone hydrochloride - OMS-527 - Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Small Molecules for Binge Eating Disorder For more information visit http://www.researchandmarkets.com/research/46...nge_eating
TEVA: 54.58 (-0.40), OMER: 11.39 (+0.23)
Binge Eating Disorder Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Wed Jun 17, 11:30AM CDT
The report "Binge Eating Disorder - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Binge Eating Disorder. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Binge Eating Disorder with 21 market data tables and 12 figures, spread across 41 pages is available at http://www.rnrmarketresearch.com/binge-eating...eport.html .
TEVA: 54.58 (-0.40), OMER: 11.39 (+0.23)
Lightlake Therapeutics Inc. - Product Pipeline Review - 2014
M2 - Tue Jun 09, 7:54AM CDT
Product Pipeline Review - 2014
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone
PR Newswire - Wed Jun 03, 8:34AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for a nasal spray formulation of naloxone, a drug intended to treat opioid overdose. A rolling submission allows completed portions of the NDA to be submitted and reviewed by the FDA on an ongoing basis.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study
PR Newswire - Wed Apr 22, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, successfully completed a clinical study of intranasal naloxone.
Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing
PR Newswire Europe - Mon Mar 09, 8:01AM CDT
- Lightlake invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view the presentation.
Lightlake Therapeutics Inc. Announces Fast Track Designation From The United States Food And Drug Administration For Intranasal Naloxone Treatment To Reverse Opioid Overdose
PR Newswire - Tue Feb 17, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited, Lightlake's partner for treating opioid overdose with intranasal naloxone, has received Fast Track designation by the United States Food and Drug Administration ("FDA" .
Binge Eating Disorder Pipeline Review, H2 2015
M2 - Tue Feb 02, 11:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/2px4r5/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Binge Eating Disorder Overview - Therapeutics Development - Pipeline Products for Binge Eating Disorder - Overview - Pipeline Products for Binge Eating Disorder - Comparative Analysis - Binge Eating Disorder - Therapeutics under Development by Companies - Binge Eating Disorder - Therapeutics under Investigation by Universities/Institutes - Binge Eating Disorder - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Binge Eating Disorder - Products under Development by Companies - Binge Eating Disorder - Products under Investigation by Universities/Institutes - Binge Eating Disorder - Companies Involved in Therapeutics Development - Eli Lilly and Company - Heptares Therapeutics Limited - Lightlake Therapeutics Inc. - Omeros Corporation - Polleo Pharma Limited - Sunovion Pharmaceuticals Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/2p...nge_eating
TEVA: 54.58 (-0.40), LLY: 80.66 (+0.07), OMER: 11.39 (+0.23)
Lightlake Therapeutics Inc.Announces Adapt Pharma Limited to Offer All U.S. High Schools a Free Narcan(R) (Naloxone Hydrochloride) Nasal Spray and Fund School-Based Opioid Overdose Education
GlobeNewswire - Wed Jan 27, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's commercial partner for NARCAN(R) Nasal Spray, has announced two national programs at the Clinton Health Matters Initiative Activation Summit to assist in efforts to address the growing risk of opioid overdose among American high school students. Traders Look to Upside - Complementary Research on Kingfisher, Lafargeholcim, Yahoo Japan and Lightlake Therapeutics
ACCESSWIRE - Wed Jan 20, 8:20AM CST
NEW YORK, NY / ACCESSWIRE / January 20, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Kingfisher PLC (OTC: KGFHY), Lafargeholcim Ltd. (OTC: HCMLY), Yahoo Japan Corp. (OTC: YAHOY) and Lightlake Therapeutics Inc. (OTC: LLTP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Facilitates NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Access to 62,000 State and Local Public Entities
GlobeNewswire - Tue Jan 19, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders announced today that Adapt Pharma Limited ("Adapt" , Lightlake's commercial partner for NARCAN(R) Nasal Spray, has, in support of White House efforts to address the opioid overdose epidemic and a community forum in Knoxville, Tennessee, announced that it has reached an agreement to facilitate the purchase of NARCAN(R) Nasal Spray by offering its discounted public interest price to 62,000 agencies in state and local government and the non-profit sector. Lightlake Therapeutics Inc. Announces Collaboration With NIDA and the Perelman School of Medicine at the University of Pennsylvania
GlobeNewswire - Wed Dec 23, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addiction, and eating disorders, announced today that an opioid antagonist drug will be tested in patients with Cocaine Use Disorder at the University of Pennsylvania. The study will be conducted by the Department of Psychiatry at the Perelman School of Medicine at the University of Pennsylvania, and is beginning recruitment in December 2015. Lightlake Therapeutics Inc. Receives Milestone Payment for U.S. Food and Drug Administration Approval of NARCAN(R) (Naloxone Hydrochloride) Nasal Spray
GlobeNewswire - Tue Dec 15, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders, announced today that it has received a $2 million milestone payment from Adapt Pharma Limited ("Adapt" . This milestone payment was triggered by the U.S. Food and Drug Administration ("FDA" approval of NARCAN(R) (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt, Lightlake's commercial partner. The FDA approved NARCAN(R) Nasal Spray on November 18, 2015. Lightlake also expects to receive a $2.5 million milestone payment from Adapt after the prospective first commercial sale of NARCAN(R) Nasal Spray in the United States. Drug Addiction - Pipeline Review Report, H2 2015
M2 - Fri Dec 04, 6:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/j3rm9n/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H2 2015" report to their offering. Drug Addiction - Pipeline Review, H2 2015 Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Drug Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Drug Addiction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Drug Addiction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Drug Addiction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics Ltd - Aphios Corporation - Astellas Pharma Inc. - Curemark, LLC - Embera NeuroTherapeutics, Inc. - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lightlake Therapeutics Inc. - Omeros Corporation - Rottapharm SpA - Saniona AB - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/j3..._addiction
TEVA: 54.58 (-0.40), OMER: 11.39 (+0.23)
NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Approved by U.S. Food and Drug Administration
GlobeNewswire - Thu Nov 19, 7:30AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders announced today that the U.S. Food and Drug Administration (FDA) has approved NARCAN(R) (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt Pharma Limited ("Adapt" , Lightlake's partner. Lightlake Therapeutics Inc. Announces FDA Accepts for Review Adapt Pharma Limited's NARCAN(R) (Naloxone Hydrochloride) Nasal Spray NDA and Grants Priority Review Status
GlobeNewswire - Fri Sep 25, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has had a New Drug Application (NDA) accepted for filing by the U.S. Food and Drug Administration (FDA) for NARCAN(R) (naloxone hydrochloride) Nasal Spray and Priority Review has been granted. NARCAN(R) Nasal Spray had previously been granted Fast Track Designation by the FDA and Adapt submitted an NDA in July 2015. Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Submits NDA To FDA For Narcan® (naloxone) Nasal Spray
PR Newswire - Wed Jul 29, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a specialty pharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Narcan® (naloxone) Nasal Spray, an investigational drug intended to treat opioid overdose. Drug Addiction Pipeline Review, H1 2015 - 11 Companies & 26 Drug Profiles
M2 - Thu Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zp3lh3/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Aphios Corporation - Curemark, LLC - Embera NeuroTherapeutics, Inc. - Gilead Sciences, Inc. - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lightlake Therapeutics Inc. - Omeros Corporation - Rottapharm SpA - Teva Pharmaceutical Industries Limited Drug Profiles - (oxazepam metyrapone) - ADX-71441 - ADX-88178 - cannabidiol - CM-1212 - CR-5542 Series - dronabinol - Drug for Dependence - GS-6637 - ibudilast - LT-22 - MC-100093 - Methoxycoronaridine - OMS-527 - Small Molecule for Drug Addiction - Small Molecule to Activate Kappa Opioid Receptor for CNS - Small Molecule to Inhibit BRD for Cocaine Dependence - Small Molecule to Inhibit Kappa Opioid Receptor for CNS - Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Small Molecules to Inhibit DAT and SERT for CNS Disorders - Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders - TV-1380 - Vaccine for Cocaine Addiction - Vaccine for Cocaine Addiction - Vaccine for Methamphetamine Addiction For more information visit http://www.researchandmarkets.com/research/zp..._addiction
GILD: 87.76 (+2.22), TEVA: 54.58 (-0.40), OMER: 11.39 (+0.23)
Binge Eating Disorder Pipeline Review 2015 - 5 Companies & 5 Drug Profiles
M2 - Wed Jun 24, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/46nvx8/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Heptares Therapeutics Ltd. - Lightlake Therapeutics Inc. - Omeros Corporation - Polleo Pharma Limited - Teva Pharmaceutical Industries Limited Drug Profiles - armodafinil - naloxone hydrochloride - OMS-527 - Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Small Molecules for Binge Eating Disorder For more information visit http://www.researchandmarkets.com/research/46...nge_eating
TEVA: 54.58 (-0.40), OMER: 11.39 (+0.23)
Binge Eating Disorder Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Wed Jun 17, 11:30AM CDT
The report "Binge Eating Disorder - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Binge Eating Disorder. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Binge Eating Disorder with 21 market data tables and 12 figures, spread across 41 pages is available at http://www.rnrmarketresearch.com/binge-eating...eport.html .
TEVA: 54.58 (-0.40), OMER: 11.39 (+0.23)
Lightlake Therapeutics Inc. - Product Pipeline Review - 2014
M2 - Tue Jun 09, 7:54AM CDT
Product Pipeline Review - 2014
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone
PR Newswire - Wed Jun 03, 8:34AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for a nasal spray formulation of naloxone, a drug intended to treat opioid overdose. A rolling submission allows completed portions of the NDA to be submitted and reviewed by the FDA on an ongoing basis. Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study
PR Newswire - Wed Apr 22, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, successfully completed a clinical study of intranasal naloxone. Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing
PR Newswire Europe - Mon Mar 09, 8:01AM CDT
- Lightlake invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view the presentation.
Lightlake Therapeutics Inc. Announces Fast Track Designation From The United States Food And Drug Administration For Intranasal Naloxone Treatment To Reverse Opioid Overdose
PR Newswire - Tue Feb 17, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited, Lightlake's partner for treating opioid overdose with intranasal naloxone, has received Fast Track designation by the United States Food and Drug Administration ("FDA" . 
